Literature DB >> 14576104

Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers.

Philip J Budge1, Jacob Lebowitz, Barney S Graham.   

Abstract

A synthetic peptide containing amino acids 77 to 95 of the intracellular GTPase RhoA has previously been shown to inhibit replication of respiratory syncytial virus (RSV) in cultured cells. We show that residues 80 to 90 of RhoA are sufficient for this activity and that the cysteine residue at position 83 is critical. Further studies with an optimal peptide sequence containing amino acids 80 to 94 of RhoA revealed that the antiviral potency of the peptide is dependent on the oxidation of cysteine 83. Size-exclusion chromatography and sedimentation equilibrium studies of the peptide comprising residues 80 to 94 revealed that it is capable of forming aggregates in both reduced and oxidized states. A peptide (83A) in which the cysteine residue is replaced by an alanine does not form dimers or higher-order aggregates and did not inhibit RSV replication at any concentration tested. These data indicate that formation of peptide multimers is necessary for the antiviral activities of RhoA-derived peptides and suggest that the observed antiviral activities of these peptides may be unrelated to the biological functions of their parent molecule.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14576104      PMCID: PMC253766          DOI: 10.1128/AAC.47.11.3470-3477.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  28 in total

1.  How RhoGDI binds Rho.

Authors:  K Longenecker; P Read; U Derewenda; Z Dauter; X Liu; S Garrard; L Walker; A V Somlyo; R K Nakamoto; A P Somlyo; Z S Derewenda
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  1999-09

2.  Membrane fusion machines of paramyxoviruses: capture of intermediates of fusion.

Authors:  C J Russell; T S Jardetzky; R A Lamb
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Functional analysis of recombinant respiratory syncytial virus deletion mutants lacking the small hydrophobic and/or attachment glycoprotein gene.

Authors:  S Techaarpornkul; N Barretto; M E Peeples
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  An open conformation of switch I revealed by the crystal structure of a Mg2+-free form of RHOA complexed with GDP. Implications for the GDP/GTP exchange mechanism.

Authors:  T Shimizu; K Ihara; R Maesaki; S Kuroda; K Kaibuchi; T Hakoshima
Journal:  J Biol Chem       Date:  2000-06-16       Impact factor: 5.157

5.  Structural characterization of the human respiratory syncytial virus fusion protein core.

Authors:  X Zhao; M Singh; V N Malashkevich; P S Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

Review 6.  Polyanions--a lost chance in the fight against HIV and other virus diseases?

Authors:  M Lüscher-Mattli
Journal:  Antivir Chem Chemother       Date:  2000-07

7.  The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate.

Authors:  S A Feldman; S Audet; J A Beeler
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

8.  Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection.

Authors:  L K Hallak; P L Collins; W Knudson; M E Peeples
Journal:  Virology       Date:  2000-06-05       Impact factor: 3.616

Review 9.  An update on respiratory syncytial virus antiviral agents.

Authors:  G A Prince
Journal:  Expert Opin Investig Drugs       Date:  2001-02       Impact factor: 6.206

10.  A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3.

Authors:  M K Pastey; T L Gower; P W Spearman; J E Crowe; B S Graham
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

View more
  6 in total

1.  Engineering and expression of a RhoA peptide against respiratory syncytial virus infection in plants.

Authors:  Benita Ortega-Berlanga; Konstantin Musiychuk; Yoko Shoji; Jessica A Chichester; Vidadi Yusibov; Omar Patiño-Rodríguez; Daniel E Noyola; Ángel G Alpuche-Solís
Journal:  Planta       Date:  2015-10-16       Impact factor: 4.116

Review 2.  Induction of protective effector immunity to prevent pathogenesis caused by the respiratory syncytial virus. Implications on therapy and vaccine design.

Authors:  Janyra A Espinoza; Susan M Bueno; Claudia A Riedel; Alexis M Kalergis
Journal:  Immunology       Date:  2014-09       Impact factor: 7.397

3.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2.

Authors:  Yamil Liscano; Jose Oñate-Garzón; Iván Darío Ocampo-Ibáñez
Journal:  Molecules       Date:  2020-11-25       Impact factor: 4.411

5.  In Silico Selection and Evaluation of Pugnins with Antibacterial and Anticancer Activity Using Skin Transcriptome of Treefrog (Boana pugnax).

Authors:  Yamil Liscano; Laura Medina; Jose Oñate-Garzón; Fanny Gúzman; Monica Pickholz; Jean Paul Delgado
Journal:  Pharmaceutics       Date:  2021-04-18       Impact factor: 6.321

Review 6.  Protein and Peptide Substances in the Treatment of Respiratory Syncytial Infection: Current State.

Authors:  Anna A Shtro; Galina D Petukhova; Aleksandra S Romanova
Journal:  Molecules       Date:  2022-03-31       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.